Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageOur Life Sciences and Diagnostics Markets segment is comprised of seven areas of activity. We provide specialty contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level.
In the company’s own words · 10-K filed Dec 22, 2025 · SEC EDGAR
Business segments
Q2 2026 · $764.0MThe company’s own SEC segment disclosure.
- Life Sciences And Diagnostics Markets$363.0M48%
- Agilent Cross Lab$289.0M38%
- Applied Markets$112.0M15%
Agilent Technologies (A) reported revenue of $1.88B in Q3 2026 (quarter ended Jul 31, 2026), up 8.1% from the same quarter a year earlier. That came with a gross margin of 55% and net income of $362M (19% of revenue). For the full year FY2025, revenue was $6.95B (+6.7% year on year) and net income $1.30B. Its largest segment in Q2 2026 (quarter ended Apr 30, 2026) was Life Sciences And Diagnostics Markets at $363M, 48% of the disclosed total, ahead of Agilent Cross Lab at 38%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
The closest names by size in the same industry